Plain-English translation of NCT04973605 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called to treat multiple myeloma that has come back or stopped responding to previous treatments. The medication will be tested on its own and also combined with other standard cancer drugs to find the safest and most effective doses. The study will help doctors understand whether this treatment can help patients whose disease has become resistant to other therapies.
Multiple myeloma often comes back or stops responding to current treatments, leaving patients with limited options. This medication targets a specific genetic change found in some myeloma patients' cancer cells, offering a potentially new approach for people who no longer benefit from existing therapies.
You likely qualify if…
You likely don't qualify if…
You will start with screening tests including blood work and a bone marrow biopsy to confirm your diagnosis and genetic changes. Then you'll receive the study medication either by itself or combined with other drugs, taken according to a schedule your doctor will explain. The trial has two parts: the first part finds the right dose, and the second part expands to more patients to confirm safety and effectiveness. You'll have regular visits for blood tests, scans, and check-ins to monitor how you're responding and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States